AIMS: Some economic costs and consequences of drug misuse and treatment were investigated among clients recruited to the National Treatment Outcome Research Study (NTORS). DESIGN: This was a longitudinal prospective cohort design comprising 549 clients recruited from 54 residential and community treatment programmes: data were collected from interviews conducted at treatment intake, at 1 year and at 2-year follow-ups. MEASUREMENTS: Treatment costs included index and other drug treatments. Costs were estimated for use of health and social care services, criminal activity and the use of criminal justice resources. Costs were based upon self-reported data collected by structured face-to-face interviews combined with unit cost estimates taken from a variety of sources. FINDINGS: Addiction treatment was costed at pound 2.9 million in the 2 years prior to index treatment, and a further pound 4.4 million in the subsequent 2 years. Economic benefits were largely accounted for by reduced crime and victim costs of crime. Crime costs fell by pound 16.1 million during the first year, and by pound 11.3 million during the second year. Health-care costs were relatively small but approximately doubled during the course of the study. The ratio of consequences to net treatment investment varied from 18 : 1 to 9.5 : 1, depending on assumptions. This is likely to be a conservative estimate of the benefit-cost ratio because many potential benefits were not estimated. CONCLUSIONS: The data showed clear economic benefits to treating drug misusers in England.
AIMS: Some economic costs and consequences of drug misuse and treatment were investigated among clients recruited to the National Treatment Outcome Research Study (NTORS). DESIGN: This was a longitudinal prospective cohort design comprising 549 clients recruited from 54 residential and community treatment programmes: data were collected from interviews conducted at treatment intake, at 1 year and at 2-year follow-ups. MEASUREMENTS: Treatment costs included index and other drug treatments. Costs were estimated for use of health and social care services, criminal activity and the use of criminal justice resources. Costs were based upon self-reported data collected by structured face-to-face interviews combined with unit cost estimates taken from a variety of sources. FINDINGS: Addiction treatment was costed at pound 2.9 million in the 2 years prior to index treatment, and a further pound 4.4 million in the subsequent 2 years. Economic benefits were largely accounted for by reduced crime and victim costs of crime. Crime costs fell by pound 16.1 million during the first year, and by pound 11.3 million during the second year. Health-care costs were relatively small but approximately doubled during the course of the study. The ratio of consequences to net treatment investment varied from 18 : 1 to 9.5 : 1, depending on assumptions. This is likely to be a conservative estimate of the benefit-cost ratio because many potential benefits were not estimated. CONCLUSIONS: The data showed clear economic benefits to treating drug misusers in England.
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: John Macleod; Lorraine Copeland; Matthew Hickman; James McKenzie; Jo Kimber; Daniela De Angelis; James R Robertson Journal: BMC Public Health Date: 2010-02-26 Impact factor: 3.295
Authors: Robert P Schwartz; Pierre K Alexandre; Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Jerome H Jaffe Journal: J Subst Abuse Treat Date: 2013-10-14
Authors: Naomi A Fineberg; Peter M Haddad; Lewis Carpenter; Brenda Gannon; Rachel Sharpe; Allan H Young; Eileen Joyce; James Rowe; David Wellsted; David J Nutt; Barbara J Sahakian Journal: J Psychopharmacol Date: 2013-07-24 Impact factor: 4.153
Authors: Nicola Metrebian; Tim Weaver; Kimberley Goldsmith; Stephen Pilling; Jennifer Hellier; Andrew Pickles; James Shearer; Sarah Byford; Luke Mitcheson; Prun Bijral; Nadine Bogdan; Owen Bowden-Jones; Edward Day; John Dunn; Anthony Glasper; Emily Finch; Sam Forshall; Shabana Akhtar; Jalpa Bajaria; Carmel Bennett; Elizabeth Bishop; Vikki Charles; Clare Davey; Roopal Desai; Claire Goodfellow; Farjana Haque; Nicholas Little; Hortencia McKechnie; Franziska Mosler; Jo Morris; Julian Mutz; Ruth Pauli; Dilkushi Poovendran; Elizabeth Phillips; John Strang Journal: BMJ Open Date: 2021-07-01 Impact factor: 2.692